Diana Mckenzie - 01 May 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
01 May 2022
Net transactions value
$0
Form type
4
Filing time
03 May 2022, 16:48:53 UTC
Previous filing
27 Apr 2022
Next filing
16 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Disposed to Issuer -1,842 -56% 1,435 01 May 2022 Direct F1
transaction VRTX Common Stock Award $0 +1,449 +101% $0.000000 2,884 01 May 2022 Direct F3
holding VRTX Common Stock 207 01 May 2022 Held in Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Deferred Stock Units Award +1,842 +207% 2,731 01 May 2022 Common Stock 1,842 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2021, Ms. McKenzie deferred the receipt of 1,842 shares of common stock and received instead 1,842 deferred stock units pursuant to the Issuer's deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 1,842 shares of common stock in exchange for an equal number of deferred stock units.
F2 Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on the Issuer's board of directors, (ii) a change of control of the Issuer and (iii) Ms. McKenzie's disability or death.
F3 Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.